RxDoctor Payments DataLook up a doctor →

Russell Canham, MD

Clinical Cardiac Electrophysiology · Dallas, TXNPI 1629288246

Payments from drug & device makers

$183,611in general payments, 2019–2025

Across 655 payments — averaging $280.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$105K
  • Lexicon Pharmaceuticals, Inc.$43K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$12K
  • Abbott$10K
  • Amarin Pharma, Inc.$9K
  • Medtronic$1K
  • plus $3K from 20 others

What the payments were for

  • Consulting fees$5,1443%
  • Speaking & faculty fees$154,97684%
  • Travel & lodging$11,3436%
  • Food & beverage$11,9587%
  • Education$1070%
  • Entertainment$830%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$183,611 in reported general payments places this provider in the 80th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$195,194
Medicare patients
255
Services billed
1,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban320$297,702
EntrestoSacubitril/Valsartan254$197,161
EliquisApixaban151$119,733
MultaqDronedarone Hcl32$37,982
FarxigaDapagliflozin Propanediol35$26,903
VascepaIcosapent Ethyl30$20,535
JardianceEmpagliflozin26$19,729
VerquvoVericiguat14$13,365
Repatha SureclickEvolocumab20$10,733
Icosapent Ethyl39$9,478
InpefaSotagliflozin11$6,853
Metoprolol Succinate415$3,602
Amiodarone Hcl118$3,362
Carvedilol452$3,160
Rosuvastatin Calcium248$2,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$105,070$297,702320 claims
NovartisEntresto$317$197,161254 claims
PfizerEliquis$226$119,733151 claims
Sanofi-aventis U.S. LLCMultaq$27$37,98232 claims
AstraZenecaFarxiga$248$26,90335 claims
Boehringer IngelheimJardiance$119$19,72926 claims
MerckVerquvo$667$13,36514 claims
Lexicon Pharmaceuticals, Inc.Inpefa$43,232$6,85311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →